We are live on ! Find out more
LVTX

LAVA Therapeutics
LVTX

Delisted

LVTX was delisted on the 20th of November, 2025.

Back to rankings

15 hedge funds and large institutions have $11.7M invested in LAVA Therapeutics in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

4% more capital invested

Capital invested by funds: $11.2M → $11.7M (+$476K)

4.26% less ownership

Funds ownership: 26.12% → 21.86% (-4.3%)

21% less funds holding

Funds holding: 19 → 15 (-4)

44% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 9

Holders
15
Holders Change
-4
Holders Change %
-21.05%
% of All Funds
0.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
3
Reduced
2
Closed
9
Calls
$35K
Puts
–
Net Calls
+$35K
Net Calls Change
+$35K

Top Buyers

Rank Fund Capital Flow
1
BC
Bruce & Co
Illinois
+$185K
2
Millennium Management
Millennium Management
New York
+$148K
3
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
+$27.7K
4
TRCT
Tower Research Capital (TRC)
New York
+$22.1K
5
HF
HRT Financial
New York
+$19.8K

Top Sellers

Rank Fund Capital Flow
1
NHAS
Novo Holdings A/S
Denmark
-$1.24M
2
Axa
Axa
France
-$375K
3
SCM
Silverarc Capital Management
Massachusetts
-$233K
4
CF
Cantor Fitzgerald
New York
-$88.5K
5
Bank of America
Bank of America
North Carolina
-$53.5K

LVTX Hedge Fund Activity: Q2 2023 in Review

15 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in LAVA Therapeutics (LVTX) for Q2 2023, worth a combined $11.7M — up 4.3% from $11.2M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of LVTX and 5 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 3 added.

The largest buyer was Bruce & Co, adding an estimated $185K. The largest seller was Novo Holdings A/S, cutting an estimated $1.24M.

  • 15 institutional investors held LAVA Therapeutics (LVTX) as of Q2 2023, down from 19 in Q1 2023.
  • Funds reported $11.7M of LAVA Therapeutics stock for Q2 2023, up 4.3% quarter-over-quarter.
  • 5 funds opened new LAVA Therapeutics positions in Q2 2023 and 9 closed out, a net change of -4 holders.
  • The largest LAVA Therapeutics buyer in Q2 2023 was Bruce & Co, an estimated $185K added.
  • The largest LAVA Therapeutics seller in Q2 2023 was Novo Holdings A/S, an estimated $1.24M sold.

Based on aggregated 13F filings for Q2 2023.